Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002592 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia
A Phase 2 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00002592 is a Phase 2 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 40 participants.
The verdict
NCT00002592, a Phase 2 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with autologous bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy followed by autologous bone marrow transplantation in treating patients with chronic myelogenous leukemia.
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL filgrastim
- DRUG busulfan
- PROCEDURE autologous bone marrow transplantation
- BIOLOGICAL c-myb antisense oligonucleotide G4460
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 1993-06 |
| Est. Completion | 2002-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002592
The ClinicalTrials.gov registry entry for NCT00002592 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00002592 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002592 about?
NCT00002592 is a clinical study titled "Chemotherapy and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with autologous bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase II tr...
What is the current status of trial NCT00002592?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 1993-06. Estimated completion is 2002-08.
What interventions are being tested in trial NCT00002592?
The interventions under investigation include: cyclophosphamide (DRUG), filgrastim (BIOLOGICAL), busulfan (DRUG), autologous bone marrow transplantation (PROCEDURE), c-myb antisense oligonucleotide G4460 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002592?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.